Knight Initiative News

This week, we talk with our founding director, Bill Newsome, about the 10-year legacy of the NIH BRAIN Initiative and the uncertainty for the future brought on by this year's dramatic funding cuts.

Supported by the Big Ideas in Neuroscience program, research from the Brunet lab suggests the possibility of designing pharmaceutical or genetic therapies to turn on new neuron production in old or injured brains.

Wu Tsai Neuro affiliate Carolyn Rodriguez directs the Stanford OCD Research Lab. She tells NPR there are still a lot of basics we have yet to understand about OCD.

Stanford undergraduates and local community college students showcased their summer research projects at the Wu Tsai Neurosciences Institute, highlighting efforts to introduce students to neuroscience research for the first time.

With support from a Wu Tsai Neuro seed grant, faculty affiliate Helen Bronte-Stewart and her team have developed a simple, portable device to help Parkinson's patients track their symptoms at home.

This week on From Our Neurons to Yours, we talk with Stanford neurologist Mike Greicius about his critique of new amyloid-clearing Alzheimer's drugs, and his optimism for the next wave of therapies currently in development.

New research by Institute affiliate Leanne Williams adds to the evidence that choosing treatment based on the neurological underpinnings of a patient’s depression increases the odds of success.

Study in mice, supported by the Knight Initiative, suggests that an experimental cancer drug boosted brain metabolism, restored memory, and improved Alzheimer's symptoms. This novel approach may offer a new way to treat Alzheimer's beyond targeting amyloid plaques.

This week on From Our Neurons to Yours, we talk with Leanne Williams about distinctive biotypes of depression revealed by brain imaging and AI, and the implications for therapy and mental health.

Research by Kati Andreasson and colleagues suggests that a type of drug developed for treating cancer may hold promise as a new treatment for neurodegenerative disorders such as Alzheimer’s.

A drug that restores brain metabolism in mouse models of Alzheimer's also improved cognitive function, according to research from the Andreasson lab.

A team of neuroscientists at the Knight Initiative for Brain Resilience have zeroed in on a critical regulator of brain metabolism that may be over-activated in the brains of patients with Alzheimer’s disease.

It may feel like you’re being more productive, but experts like Anthony Wagner say you’re not.

Time marches on predictably, but biological aging is anything but constant, according to new research by Michael Snyder and colleagues.

This week on From Our Neurons to Yours, we talk with Michelle Monje about her discovery that many cancers depend on nervous system innervation; she also discusses opportunities for novel therapies.

The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease, but which also carry safety risks according to Knight Initiative for Brain Resilience affiliate Mike Greicius and others.

Experts at Stanford Medicine Children’s Health helped conduct clinical trials for the new therapy, which gives kids with X-linked adrenoleukodystrophy, or ALD, a functioning copy of the abnormal gene.

To advance neuroscience research using EEG and TMS technologies, the Koret Human Neurosciences Community Lab has awarded its inaugural Human Neuroscience Pilot Grants to ten innovative research projects.

This week on From Our Neurons to Yours, we talk with anesthesiologist Boris Heifets about how psychedelics work in the brain.

Recognizing the potential for wider application in small-animal neuroscience research, the Neurosciences Preclinical Imaging Lab (NPIL) at Wu Tsai Neuro hosted its 3rd annual symposium and named the recipients of its Pilot Grants.